about
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutationsDiscovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant virusesSubstituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutantsBiaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
P50
name
Rebecca Perlow-Poehnelt
@ast
Rebecca Perlow-Poehnelt
@en
Rebecca Perlow-Poehnelt
@es
Rebecca Perlow-Poehnelt
@nl
type
label
Rebecca Perlow-Poehnelt
@ast
Rebecca Perlow-Poehnelt
@en
Rebecca Perlow-Poehnelt
@es
Rebecca Perlow-Poehnelt
@nl
prefLabel
Rebecca Perlow-Poehnelt
@ast
Rebecca Perlow-Poehnelt
@en
Rebecca Perlow-Poehnelt
@es
Rebecca Perlow-Poehnelt
@nl